SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

OTLKW (OTLKW) News

Follow OTLKW (OTLKW) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 7 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol OTLKW Asset equity Sector Markets 90 days 3 Last 0.05 Updated Sep 10, 2026, 01:10 PM UTC Open live news feed Open OTLKW chart & news
L OTLK OTLKW - Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Con OTLK OTLKW - Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment REGULATION | Sep 10, 2026, 01:10 PM UTC L Outlook Therapeutics appoints CFO Kevin Lundquist Outlook Therapeutics appointed Kevin Lundquist as chief financial officer as it prepares for a U.S. commercial launch of LYTENAVA. EQUITY | Aug 27, 2026, 08:06 PM UTC L OTLK OTLKW - Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference OTLK OTLKW - Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference EQUITY | Aug 27, 2026, 01:01 PM UTC L Outlook Therapeutics reports FY2026 Q3 results; highlights LYTENAVA FDA approval Outlook Therapeutics (OTLKW) reports Third Quarter Fiscal Year 2026 financial results and a business update highlighting FDA approval of LYTENAVA™. EARNINGS | Aug 14, 2026, 11:15 AM UTC L Outlook Therapeutics prices $55.0 million common stock and warrants offering Outlook Therapeutics announces the pricing of a $55.0 million public offering of common stock and warrants, selling $55.0 million total under the priced terms. EQUITY | Aug 13, 2026, 01:45 AM UTC L OTLK OTLKW - Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants OTLK OTLKW - Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants EQUITY | Aug 12, 2026, 08:02 PM UTC L OTLK OTLKW - Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and OTLK OTLKW - Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026 EARNINGS | Aug 06, 2026, 12:45 PM UTC